Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

 

Reality Check on Anemia — Chronic Kidney Disease

Market access for anemia treatments due to chronic kidney disease reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, more than 56% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In October 2018, UnitedHealthcare said that starting Jan. 1, 2019, it would require step therapy prior authorization for Part B covered items that are not preferred for new starts. The plan will prefer biosimilar Retacrit (epoetin alfaepbx) over Procrit (epoetin alfa) and Aranesp (darbepoetin alfa)
  • Key Findings: Contracting determines preferred products, and patients may have to try and fail a preferred product first  

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.

MMIT-RC_Thumbnail_1-1.png